Evommune's EVO756 Shows Promising Results in Treating Chronic Inducible Urticaria Through Phase 2 Trials
Evommune's Breakthrough in Treating Chronic Inducible Urticaria
On May 28, 2025, Evommune, Inc., a pioneering biotechnology company based in Palo Alto, revealed impressive top-line data from their Phase 2 trial of the investigational drug EVO756. Specifically designed to treat chronic inducible urticaria (CIndU), EVO756 is a potent and selective oral small-molecule antagonist of the mas-related G-protein coupled receptor X2 (MRGPRX2). The results indicate promising efficacy and a favorable safety profile, marking a potential game-changer for patients riddled with this condition.
Key Findings from the Trial
The results from the trial, which included 30 patients experiencing symptomatic dermographism — the most prevalent form of CIndU — were unequivocally positive. Notably, 30% of participants achieved a complete response within just four weeks of treatment. Among these, 50% had elevated IgE levels (≥100 IU/ml), a common trait among individuals with chronic urticaria. Moreover, 41% of patients experienced a clinically significant reduction in itch levels, as measured by a 2-point decrease in the itch numerical rating scale.
Luis Peña, President and CEO of Evommune, stated,
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.